Citation Tools
Clinical/translational cancer immunotherapy
Original research
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies